Detection of PIK3CA mutations from ctDNA in locally recurrent unresectable or metastatic HR–positive and HER2-negative breast cancer can be treated with phosphatidylinositol 3-kinase inhibitor, alpelisib plus fulvestrant [101]. Here, PIK3CA is linked to breast cancer.